Behcet's disease is a multisystem disease characterized by recurrent oral and genital ulcers, relapsing uveitis, mucocutaneous, articular, gastrointestinal, neurologic, and vascular manifestations. Rheumatologic manifestations may also occur in Behcet's disease, and arthritis and arthralgia are the most common musculoskeletal findings followed by enthesopathy, avascular necrosis, myalgia, and myositis. Although the main pathology of Behcet's disease has been known to be the underlying vasculitis, the etiology and exact pathogenesis of the disease are still unclear. Musculoskeletal findings of Behcet's disease, the relationship between Behcet's disease and spondyloarthropathy disease complex, and the status of bone metabolism in patients with Behcet's disease were discussed in this paper. 1. Introduction Behcet’s disease (BD) is a chronic and recurrent multisystemic disorder, mainly characterized by oral and genital aphthous ulcers, skin lesions, and uveitis, occasionally resulting from inflammation in central nervous and gastrointestinal system, lungs, kidneys, and joints [1]. Additionally, BD is described as a systemic, vasculitic disorder in which both arteries and veins of any kind of organ may involve [2]. The disease may be distributed worldwide, but it is more prevalent in Asian and Mediterranean regions [3]. The etiology and pathogenesis of BD still remain obscure. However, both genetic and environmental factors, such as microbial pathogens, have been proposed to initiate a congenital and/or acquired immune dysfunction that cause development of the clinical manifestations of the disease [4]. Musculoskeletal involvement in BD is one of the most frequent findings among the clinical manifestations. Table 1 summarizes the musculoskeletal findings of BD, found in the medical literature. Arthritis and arthralgia are the most common musculoskeletal findings of the disease [5]. Although the frequency of the arthritis has been increasing, it has not been yet included in any International Study Group (ISG) Criteria of BD [6]. Furthermore, it was also claimed that the disease could be classified into the spondyloarthropathy (SpA) complex, because of the presence of sacroiliitis in BD and the clinical overlap between BD and some disease of the SpA complex [7]. On the other hand, the chronicity and factors involved in inflammatory process of the disease and the drugs used for the treatment of BD might have negative effects on bone remodeling, consequently resulting in osteoporosis in BD [8]. Table 1: Rheumatologic findings reported in medical literature. In
References
[1]
B. J. Fessler, “Vasculitis and related diseases,” in Arthritis and Allied Conditions, W. J. Koopman and L. W. Moreland, Eds., pp. 1835–1844, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 2005.
[2]
M. Onder and M. A. Gurer, “The multiple faces of Behcet's disease and its etiological factors,” Journal of the European Academy of Dermatology and Venereology, vol. 15, pp. 126–136, 2001.
[3]
T. Sakane, M. Takeno, N. Suzuki, and G. Inaba, “Behcet's disease,” New England Journal of Medicine, vol. 341, no. 17, pp. 1284–1291, 1999.
[4]
H. Ideguchi, A. Suda, M. Takeno, A. Ueda, S. Ohnu, and Y. Ishigatsubo, “Behcet’s disease: evaluation of clinical manifestations,” Medicine, vol. 90, pp. 125–132, 2011.
[5]
H. Yazici, S. Yurdakul, V. Hamuryudan, and I. Fresko, “Behcet’s syndrome,” in Rheumatology, J. H. Klippel and P. A. Dieppe, Eds., pp. 1665–1670, Mosby, London, UK, 2003.
[6]
A. Gur, A. J. Sarac, Y. K. Burkan, K. Nas, and R. Cevik, “Arthropathy, quality of life, depression, and anxiety in Behcet's disease: relationship between arthritis and these factors,” Clinical Rheumatology, vol. 25, no. 4, pp. 524–531, 2006.
[7]
H. K. Chang, D. H. Lee, S. M. Jung et al., “The comparison between Beh？et's disease and spondyloarthritides: does Beh？et's disease belong to the spondyloarthropathy complex?” Journal of Korean Medical Science, vol. 17, no. 4, pp. 524–529, 2002.
[8]
A. Bicer, U. Tursen, T. I. Kaya et al., “Bone mineral density in patients with Beh？et's disease,” Rheumatology International, vol. 24, no. 6, pp. 355–358, 2004.
[9]
S. Yurdakul, H. Yaz？c？, Y. Tuzun, et al., “The arthritis of Behcet’s disease: prospective study,” Annals of the Rheumatic Diseases, vol. 42, pp. 505–515, 1983.
[10]
C. Ben Taarit, S. Turki, and H. Ben Ma？z, “Rheumatologic manifestations of Beh？et's disease: concerning 309 cases,” Revue de Medecine Interne, vol. 22, no. 11, pp. 1049–1055, 2001.
[11]
M. Ait Ouazar and R. Niamane, “Erosive wrist arthritis: a rare manifestation of Beh？et's disease,” Revue de Medecine Interne, vol. 31, no. 7, pp. e15–e16, 2010.
[12]
N. Düzgün and A. Ate？, “Erosive arthritis in a patient with Beh？et's disease,” Rheumatology International, vol. 23, no. 5, pp. 265–267, 2003.
[13]
M. Yurtkuran, M. Yurtkuran, A. Alp et al., “Hand involvement in Behcet’s disease,” Joint Bone Spine, vol. 73, no. 6, pp. 679–683, 2006.
[14]
H. A. Kim, K. W. Choi, and Y. W. Song, “Arthropathy in Behcet's disease,” Scandinavian Journal of Rheumatology, vol. 26, no. 2, pp. 125–129, 1997.
[15]
M. A. Chamberlain and R. J. H. Robertson, “A controlled study of sacroiliitis in Behcet's disease,” British Journal of Rheumatology, vol. 32, no. 8, pp. 693–698, 1993.
[16]
N. Dilsen, M. Konice, and O. Aral, “Why Behcet's disease should be accepted as a seronegative arthritis,” in Recent Advances in Behcet's Disease, T. Lehner and C. G. Barns, Eds., pp. 281–284, Royal Society of MedicineServices, London, UK, 1986.
[17]
F. Crozier, J. Arlaud, P. Tourniaire et al., “Manubrio-sternal arthritis and Behcet's disease: report of 3 cases,” Journal de Radiologie, vol. 84, no. 12 I, pp. 1978–1981, 2003.
[18]
N. Caporn, E. R. Higgs, P. A. Dieppe, and I. Watt, “Arthritis in Behcet's syndrome,” British Journal of Radiology, vol. 56, no. 662, pp. 87–91, 1983.
[19]
M. Kirnap, M. Calis, N. Kaya, and S. Muhtaroglu, “Is the Behcet's disease a risk factor for osteoporosis and is relation to cytokines?” Bratislavské Lekárske Listy, vol. 111, no. 6, pp. 340–344, 2010.
[20]
M. Kr？mer, M. W. Baumg？rtel, E. Neuen-Jacob, and P. Berlit, “Medication side effects or expression of underlying disease,” Zeitschrift fur Rheumatologie, vol. 67, no. 3, pp. 232–236, 2008.
[21]
S. Yavuz, I. Fresko, V. Hamuryudan, S. Yurdakul, and H. Yazici, “Fibromyalgia in Behcet's syndrome,” Journal of Rheumatology, vol. 25, no. 11, pp. 2219–2220, 1998.
[22]
M. J？ger, F. Thorey, A. Wild, M. Voede, and R. Krauspe, “Osteonecrosis of Beh？et's disease: diagnosis, therapy, and course,” Zeitschrift fur Rheumatologie, vol. 62, no. 4, pp. 390–394, 2003.
[23]
F. Frikha, S. Marzouk, N. Kaddour, M. Frigui, and Z. Bahloul, “Destructive arthritis in Beh？et's disease: a report of eight cases and literature review,” International Journal of Rheumatic Diseases, vol. 12, no. 3, pp. 250–255, 2009.
[24]
T. Gibson, R. Laurent, J. Highton, M. Wilton, M. Dyson, and R. Millis, “Synovial histopathology of Behcet’s syndrome,” Annals of the Rheumatic Diseases, vol. 40, pp. 376–381, 1981.
[25]
C. Moll, M. Bogas, J. A. Gómez-Puerta et al., “Macroscopic features of knee synovitis in early untreated Beh？et disease and psoriatic arthritis,” Clinical Rheumatology, vol. 28, no. 9, pp. 1053–1057, 2009.
[26]
J. D. Ca？ete, R. Celis, T. Noordenbos et al., “Distinct synovial immunopathology in Beh？et disease and psoriatic arthritis,” Arthritis Research and Therapy, vol. 11, no. 1, article R17, 2009.
[27]
H. Yazici and I. Fresko, “Beh？et's disease and other autoinflammatory conditions: what's in a name?” Clinical and Experimental Rheumatology, vol. 23, no. 4, pp. S1–S2, 2005.
[28]
D. S. Gibson, J. Banha, D. Penque et al., “Diagnostic and prognostic biomarker discovery strategies for autoimmune disorders,” Journal of Proteomics, vol. 73, no. 6, pp. 1045–1060, 2010.
[29]
A. Gül, “Beh？et's disease as an autoinflammatory disorder,” Current Drug Targets, vol. 4, no. 1, pp. 81–83, 2005.
[30]
B. Wechsler, F. Davatchi, Y. Mizushima et al., “Criteria for diagnosis of Behcet's disease,” Lancet, vol. 335, no. 8697, pp. 1078–1080, 1990.
[31]
G. Hatemi, A. Silman, D. Bang et al., “EULAR recommendations for the management of Beh？et disease,” Annals of the Rheumatic Diseases, vol. 67, no. 12, pp. 1656–1662, 2008.
[32]
A. El Maghraoui, F. Tabache, A. Bezza et al., “A controlled study of sacroiliitis in Beh？et's disease,” Clinical Rheumatology, vol. 20, no. 3, pp. 189–191, 2001.
[33]
N. Dilsen, M. Konice, and O. Aral, “Why Behcet’s disease should be accepted as a seronegative arthritis,” in Recent Advances in Behcet’s Disease, T. Lehner and C. G. Barnes, Eds., pp. 281–284, Royal Society of Medicine Services, London, UK, 1986.
[34]
H. Yazici, M. Tuzlaci, and S. Yurdakul, “A controlled survey of sacroiliitis in Behcet's disease,” Annals of the Rheumatic Diseases, vol. 40, no. 6, pp. 558–559, 1981.
[35]
G. Hatemi, I. Fresko, K. Tascilar, and H. Yazici, “Increased enthesopathy among Beh？et's syndrome patients with acne and arthritis: an ultrasonography study,” Arthritis and Rheumatism, vol. 58, no. 5, pp. 1539–1545, 2008.
[36]
N. Sakly, R. Boumiza, S. Zrour-Hassen et al., “HLA-B27 and HLA-B51 determination in Tunisian healthy subjects and patients with suspected ankylosing spondylitis and Beh？et's disease,” Annals of the New York Academy of Sciences, vol. 1173, pp. 564–569, 2009.
[37]
E. Diri, C. Mat, V. Hamuryudan, S. Yurdakul, N. Hizli, and H. Yazici, “Papulopustular skin lesions are seen more frequently in patients with Beh？et's syndrome who have arthritis: a controlled and masked study,” Annals of the Rheumatic Diseases, vol. 60, no. 11, pp. 1074–1076, 2001.
[38]
B. L. Hazleman, “Rheumatic disorders of the eye and the various structures involved,” British Journal of Rheumatology, vol. 35, no. 3, pp. 258–268, 1996.
[39]
T. D. Rachner, S. Khosla, and L. C. Hofbauer, “Osteoporosis: now and the future,” The Lancet, vol. 377, no. 9773, pp. 1276–1287, 2011.
[40]
R. R. McLean, “Proinflammatory cytokines and osteoporosis,” Current Osteoporosis Reports, vol. 7, no. 4, pp. 134–139, 2009.
[41]
B. Wechsler, L. T. Huong, C. De Gennes et al., “Arterial involvement in Behcet's disease. Report of 12 cases,” Revue de Medecine Interne, vol. 10, no. 4, pp. 303–311, 1989.
[42]
J. L. Jorizzo, R. D. Hudson, and F. C. Schmalstieg, “Behcet's syndrome: immune regulation, circulating immune complexes, neutrophil migration, and colchicine therapy,” Journal of the American Academy of Dermatology, vol. 10, no. 2, pp. 205–214, 1984.
[43]
C. Evereklioglu, H. Er, Y. Türk？z, and M. ？ekmen, “Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh？et's disease,” Mediators of Inflammation, vol. 11, no. 2, pp. 87–93, 2002.
[44]
M. O. Oztas, M. Onder, M. A. Gurer, N. Bukan, and B. Sancak, “Serum interleukin 18 and tumour necrosis factor-α levels are increased in Behcet's disease,” Clinical and Experimental Dermatology, vol. 30, no. 1, pp. 61–63, 2005.
[45]
K. Hamzaoui, I. B. Dhifallah, E. Karray, F. H. Sassi, and A. Hamzaoui, “Vitamin D modulates peripheral immunity in patients with Beh？et's disease,” Clinical and Experimental Rheumatology, vol. 28, no. 4, pp. S50–S57, 2010.
[46]
N. S. Tekin, S. Ozdolap, S. Sarikaya, E. Esturk, and S. Gumustas, “Bone mineral density and bone turnover markers of patients with Beh？et's disease,” Journal of the European Academy of Dermatology and Venereology, vol. 21, no. 1, pp. 25–29, 2007.
